Quality of life of individuals with neuromuscular disease: a national cross-sectional survey

To describe health utility scores among individuals living with neuromuscular disorders (NMDs) and examine sociodemographic, clinical, and economic factors associated with these outcomes. We conducted a nationwide, cross-sectional survey of individuals with NMDs and caregivers enrolled with Muscular Dystrophy Canada. Health-related quality of life (HRQoL) was assessed in adults using the Health Utilities Index Mark 3 (HUI3) and in minors using parent-proxy responses to the Pediatric Quality of Life Inventory Neuromuscular Module (PedsQL-NMM). Multivariable generalized linear models were used. The sample included 850 adults (mean [SD] age, 56 [16] years, 52% female) and 94 minors (mean [SD] age, 11 [5] years, 44% female). Mean HUI3 score was 0.27 (SD:0.31) and mean PedsQL-NMM score was 45.9 (SD: 18.7). Among adults, lower HUI3 was associated with moderate/severe financial toxicity (RR, 0.43; 95% CI: 0.35, 0.53), longer disease duration (RR per 5-year increase, 0.97; 95% CI: 0.96, 0.99), autoimmune myopathies (RR, 0.87; 95% CI: 0.79, 0.95), Charcot-Marie-Tooth disease or genetic neuropathies (RR, 0.72; 95% CI: 0.60, 0.86), spinal and bulbar muscular atrophy (RR, 0.81; 95% CI: 0.67, 0.98), inability to work (RR, 0.49; 95% CI: 0.37, 0.65), retirement (RR, 0.81; 95% CI: 0.74, 0.89) and early retirement (RR, 0.66; 95% CI: 0.53, 0.83). Among minors, PedsQL-NMM scores were higher at ages 10–14 versus 0–4 years (RR = 1.47, 95% CI: 1.12, 1.93). NMDs are associated with marked reductions in HRQoL. Disease heterogeneity, financial strain, and social factors should be considered in economic evaluations and health policy decision-making for NMDs. • Neuromuscular diseases (NMDs) are chronic, often progressive conditions associated with weakness, functional limitations, and reduced participation in work and daily activities. However, population-based evidence describing health related quality of life (HRQoL) among NMD populations remains limited. • This national study of 850 adults and 94 minors with NMDs demonstrated substantial reductions in HRQoL across age groups (mean HUI3 0.27; PedsQL-NMM 45.9) and identified financial toxicity, employment disruption, disease duration and selected clinical characteristics as major determinants of HRQoL. • Findings highlight the need to incorporate socioeconomic burden and disease heterogeneity into economic evaluations and policy decisions for NMD populations.

Authors

Institutions

Publication Details

Journal
Health and Quality of Life Outcomes
Published
2026-11-11
DOI
https://doi.org/10.1186/s12955-026-02659-w
Primary Topic
Health Systems, Economic Evaluations, Quality of Life
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Quality of life of individuals with neuromuscular disease: a national cross-sectional survey

Stacey Lintern, Homira Osman, Jodi Warman‐Chardon, Kathryn A. Selby et al.
Health and Quality of Life Outcomes
Health Systems, Economic Evaluations, Quality of Life
article

Quality of life of individuals with neuromuscular disease: a national cross-sectional survey

Stacey Lintern, Homira Osman, Jodi Warman‐Chardon, Kathryn A. Selby, Lawrence W. Korngut, Lola Lessard, Timothy E. Shutt, Cynthia Gagnon, Hanns Lochmüller, Ari Breiner, Kednapa Thavorn, Alyssa Grant, Hugh J. McMillan, Ian C. P. Smith
article en

Abstract

To describe health utility scores among individuals living with neuromuscular disorders (NMDs) and examine sociodemographic, clinical, and economic factors associated with these outcomes. We conducted a nationwide, cross-sectional survey of individuals with NMDs and caregivers enrolled with Muscular Dystrophy Canada. Health-related quality of life (HRQoL) was assessed in adults using the Health Utilities Index Mark 3 (HUI3) and in minors using parent-proxy responses to the Pediatric Quality of Life Inventory Neuromuscular Module (PedsQL-NMM). Multivariable generalized linear models were used. The sample included 850 adults (mean [SD] age, 56 [16] years, 52% female) and 94 minors (mean [SD] age, 11 [5] years, 44% female). Mean HUI3 score was 0.27 (SD:0.31) and mean PedsQL-NMM score was 45.9 (SD: 18.7). Among adults, lower HUI3 was associated with moderate/severe financial toxicity (RR, 0.43; 95% CI: 0.35, 0.53), longer disease duration (RR per 5-year increase, 0.97; 95% CI: 0.96, 0.99), autoimmune myopathies (RR, 0.87; 95% CI: 0.79, 0.95), Charcot-Marie-Tooth disease or genetic neuropathies (RR, 0.72; 95% CI: 0.60, 0.86), spinal and bulbar muscular atrophy (RR, 0.81; 95% CI: 0.67, 0.98), inability to work (RR, 0.49; 95% CI: 0.37, 0.65), retirement (RR, 0.81; 95% CI: 0.74, 0.89) and early retirement (RR, 0.66; 95% CI: 0.53, 0.83). Among minors, PedsQL-NMM scores were higher at ages 10–14 versus 0–4 years (RR = 1.47, 95% CI: 1.12, 1.93). NMDs are associated with marked reductions in HRQoL. Disease heterogeneity, financial strain, and social factors should be considered in economic evaluations and health policy decision-making for NMDs. • Neuromuscular diseases (NMDs) are chronic, often progressive conditions associated with weakness, functional limitations, and reduced participation in work and daily activities. However, population-based evidence describing health related quality of life (HRQoL) among NMD populations remains limited. • This national study of 850 adults and 94 minors with NMDs demonstrated substantial reductions in HRQoL across age groups (mean HUI3 0.27; PedsQL-NMM 45.9) and identified financial toxicity, employment disruption, disease duration and selected clinical characteristics as major determinants of HRQoL. • Findings highlight the need to incorporate socioeconomic burden and disease heterogeneity into economic evaluations and policy decisions for NMD populations.

Health and Quality of Life Outcomes
Centre National de la Recherche Scientifique (FR), Université de Sherbrooke (CA), University of Ottawa (CA), Inserm (FR), University of Calgary (CA), Children's Hospital of Eastern Ontario (CA), Muscular Dystrophy Canada (CA), Ottawa Hospital (CA), Hospices Civils de Lyon (FR), Institut NeuroMyoGène (FR), BC Children's Hospital (CA), Laboratoire Physiopathologie et Génétique du Neurone et du Muscle (FR), Ottawa Hospital Research Institute (CA), Hotchkiss Brain Institute (CA)
Health Systems, Economic Evaluations, Quality of Life
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon